A Prediction Rule for Overall Survival in Non-Small-Cell Lung Cancer Patients with a Pathological Tumor Size Less Than 30 mm

Table 1

The overall survival of the training set and validation set in NSCLC patients with a pathological tumor size less than 30 mm.

Patient characteristics	Training set ()				Validation set ()
	Patients (#)	Patients (%)	OS (months)		Patients (#)	Patients (%)	OS (months)
			Median	95% CI			Median	95% CI
Sex
Male	193	42.2	92.7	85.3-100.0	113	34.3	38.0	37.1-38.9
Female	264	57.8	117.4	111.5-123.2	216	65.7	38.8	38.5-39.1
Age (y), median (IQR)	60 (52-66)				57 (51-65)
<60	223	48.8	114.8	108.4-121.2	186	56.5	38.5	38.0-39.0
≥60	234	51.2	100.8	93.8-107.8	143	43.5	38.5	38.2-38.9
Smoking
Never smoker	315	68.9	114.1	108.4-119.7	258	78.4	38.8	38.6-39.1
Current/former smoker	142	31.1	91.8	83.4-100.1	71	21.6	37.4	38.6-39.1
Preoperational CEA level (ng/mL), median (IQR)	1.95 (1.28-3.27)				1.75 (1.14-2.79)
<5.0	395	86.6	108.7	103.9-113.4	297	90.5	38.7	38.4-39.0
≥5.0	61	13.4	82.3	68.4-96.2	31	9.5	35.8	33.2-38.3
Type of surgery
Lobectomy	383	83.8	107.4	102.2-112.5	127	38.6	38.7	38.4-39.1
Limited resection	74	16.2	91.4	78.5-104.3	202	61.4	38.2	37.4-38.9
Tumor location
Right upper lobe	161	35.2	110.1	102.6-117.6	118	35.9	NA
Right middle lobe	35	7.7	117.3	102.0-132.6	34	10.3
Right lower lobe	68	14.9	87.6	75.5-99.6	56	17.0
Left upper lobe	124	27.1	114.1	104.4-123.9	88	26.8
Left lower lobe	58	12.7	97.4	85.0-109.8	31	9.4
Undefined	11	2.4	72.9	43.5-102.2	2	0.6
Histology
AIS & MIA	195	42.7	127.6	124.8-130.4	195	59.3	38.9	38.8-39.1
IAC	198	43.3	97.6	89.8-105.4	123	37.4	38.0	37.1-38.9
SCC	64	14.0	73.6	62.4-84.8	11	3.3	33.2	31.7-34.7
Pathological tumor size (mm), median (IQR)	15 (9-20)
≤10 mm	156	34.1	126.0	121.5-130.5	180	54.7	38.9	38.8-39.1
>10-20 mm	196	42.9	107.3	100.6-114.1	106	32.2	38.3	37.5-39.1
>20-30 mm	105	23.0	81.3	71.1-91.5	43	13.1	37.5	35.8-39.1
Lymph node metastasis
N0	402	88.0	114.1	109.3-119.0	311	94.5	38.8	38.5-39.1
N1	23	5.0	65.2	45.9-84.6	5	1.5	26.9	21.5-32.3
N2	32	7.0	54.4	62.4-84.8	13	4.0	34.2	31.1-37.3
Pathological TNM stage
0	111	24.4	128.7	126.1-131.2	99	30.1	NA
IA1	77	16.8	110.9	100.1-121.7	92	28.0
IA2	138	30.2	105.5	96.8-114.1	89	27.0
IA3	77	16.8	91.8	79.7-104.0	31	9.4
IIB	23	5.0	65.2	45.9-84.6	5	1.5
IIIA	31	6.8	54.8	42.1-67.5	13	4.0
P53 expression
Negative	208	72.5	83.3	80.7-85.9	211	75.1	38.8	38.5-39.1
Positive	79	27.5	68.2	61.2-75.2	70	24.9	36.5	35.2-37.7
Ki-67 expression
<10%	203	70.7	84.2	81.4-87.1	186	65.7	38.9	38.7-39.1
≥10%	84	29.3	67.6	61.2-74.0	97	34.3	37.6	36.5-38.7
EGFR mutation
Wild type	190	70.9	76.9	74.8-78.9	182	55.7	38.3	37.7-38.9
Mutation	78	29.1	71.4	64.7-78.0	145	44.3	38.8	38.4-39.2

IQR: interquartile range; CEA: carcinoembryonic antigen; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IAC: invasive adenocarcinoma; SCC: squamous cell lung cancer; EGFR: epidermal growth factor receptor.